triple negative breast cancer

November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

By Bill Snyder
Deanna Edwards, PhD, left, Jin Chen, MD, PhD, and colleagues are studying a new therapeutic strategy for triple-negative breast cancer.
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.

By Leigh MacMillan
June 4, 2020

Potential new cancer target

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.

By Bill Snyder
March 12, 2020

Triple-negative breast cancer drug therapy shows promise

Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.

By Tom Wilemon
February 27, 2020

Breast cancer study may help predict treatment response

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

By Bill Snyder
July 8, 2019

Clinical study tests drug that may prevent cancer metastasis

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

By Leigh MacMillan
November 18, 2016

Targeting the “un-targetable”

A novel drug that targets the protein RSK blocked aggressive breast cancers from metastasizing in an animal model.
By VUMC News and Communications
September 9, 2016

In search of new cancer targets

Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers.
By Leigh MacMillan
April 21, 2016

Study explores how some breast cancers resist treatment

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.
By VUMC News and Communications
July 31, 2014

New target for breast cancer therapy

The protein MTBP is overexpressed in an aggressive type of breast cancer, and it regulates another protein implicated in many cancer types, suggesting that it may be a good target for new therapeutics.
By Leigh MacMillan
March 21, 2013

Breast cancer study explores therapy to slow recurrence

Many patients with triple-negative breast cancer (TNBC) have recurrence of their disease after an initial response to chemotherapy because the cancer cells have become resistant to treatment. TNBC has a lower survival rate because of this pattern of resistance and there are no targeted agents to treat this form of breast cancer.
By VUMC News and Communications